Canaccord Genuity Group initiated coverage on shares of Nuformix (LON:NFX – Free Report) in a research note issued to investors on Tuesday,Digital Look reports. The brokerage issued a buy rating and a GBX 293 ($3.80) price target on the stock.
Nuformix Stock Performance
NFX stock opened at GBX 0.09 ($0.00) on Tuesday. Nuformix has a 52 week low of GBX 0.04 ($0.00) and a 52 week high of GBX 0.30 ($0.00). The firm’s fifty day moving average is GBX 0.08 and its 200 day moving average is GBX 0.07. The firm has a market cap of £1.12 million, a P/E ratio of -2.76 and a beta of 1.22.
Nuformix (LON:NFX – Get Free Report) last released its earnings results on Wednesday, January 29th. The company reported GBX (0.46) (($0.01)) EPS for the quarter.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
See Also
- Five stocks we like better than Nuformix
- Earnings Per Share Calculator: How to Calculate EPS
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- Compound Interest and Why It Matters When Investing
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
- What is a Low P/E Ratio and What Does it Tell Investors?
- Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
